What is the main advantage of in vivo phage display over in vitro screening?

In vivo screening accounts for the complex physiological environment, including blood flow, enzymatic degradation, and the native 3D conformation of endothelial receptors, which are often lost in cell culture.

How many rounds of panning are typically required for vascular targeting?

Usually, 3 to 4 rounds are sufficient to achieve significant enrichment of tissue-specific clones.

Can you target specific parts of an organ, such as the glomerulus in the kidney?

Yes, by using specialized histological recovery techniques or laser capture microdissection, we can isolate phages from specific sub-anatomical regions.

What phage types do you use for in vivo screening?

We primarily use filamentous M13 phages for peptide display due to their stability, but T7 lytic phages are also available for applications requiring larger inserts or different display properties.

How do you prevent the library from being cleared by the liver or spleen?

We use "pre-adsorption" techniques and optimized circulation times. We also offer modified phage scaffolds designed to evade the Reticuloendothelial System (RES).

Is NGS mandatory for your service?

While not mandatory, we highly recommend it. NGS provides a much broader view of the library's evolution and helps identify high-affinity binders that might be outcompeted by "faster growers" in traditional Sanger sequencing.

Can the identified peptides be used in humans?

The peptides discovered in animal models often require "humanization" or validation in human tissue sections/NHP models, which we also provide. Many motifs (like RGD) are highly conserved across species.

What is the typical library diversity you provide?

Our standard libraries have a diversity of 10^9 to 10^11 unique clones.

Do you provide the chemical synthesis of the identified lead peptides?

Yes, we provide full peptide synthesis and modification services, including cyclization, D-amino acid substitution, and conjugation to payloads.

How do you ensure the phages are actually binding to the endothelium and not just stuck in the blood?

Through rigorous systemic perfusion with high volumes of buffer, which flushes out all non-adherent phages from the vascular lumen.

Can this service be used for identifying biomarkers of vascular inflammation?

Absolutely. We can compare phage enrichment between healthy animals and those with induced vascular inflammation to find unique biomarkers of disease.

In Vivo Phage Library Screening Service for Vascular Endothelium Targeting

Background Platform Workflow Application Advantage Related Service FAQ Online Inquiry

In the rapidly evolving landscape of precision medicine and targeted drug delivery, the vascular endothelium stands as the most critical biological interface. As the primary barrier and gateway between the systemic circulation and the parenchyma of every organ, the endothelium expresses a highly heterogeneous array of molecular "ZIP codes" that define tissue identity and disease states. Creative Biolabs, a global leader in phage display technology with over two decades of specialized expertise, offers the most comprehensive Vascular Endothelium Targeting In Vivo Phage Library Screening Service in the industry. Our platform integrates high-diversity combinatorial libraries, advanced animal models, and Next-Generation Sequencing (NGS) to map the vascular landscape with unprecedented resolution.

Discuss Your Project Today

The Biological Frontier: Vascular Endothelium Diversity

The vascular endothelium is not merely a passive lining of blood vessels; it is a dynamic, multi-functional organ. Its molecular composition varies significantly across different anatomical sites, influenced by local hemodynamics, oxygen tension, and tissue-specific signaling. This molecular diversity provides a unique opportunity for In Vivo Phage Display for Vascular Endothelium, allowing for the discovery of ligands that can bypass systemic degradation and home specifically to a target organ or pathological lesion.

The "ZIP Code" Hypothesis

The concept of vascular "addressing" suggests that endothelial cells in the brain, lung, heart, or tumors express distinct surface markers (receptors, integrins, or peptidases). By utilizing In Vivo Phage Library Screening, we can identify the specific keys (peptides or scFv/Fab fragments) that fit these molecular locks.

Pathological Neo-Address

Beyond physiological diversity, disease states such as cancer, inflammation, and atherosclerosis induce the expression of "neo-addresses." For instance, tumor-associated vessels often overexpress aminopeptidase N (CD13) or αvβ3 integrins. Our screening service is designed to isolate ligands that specifically recognize these upregulated markers, providing a foundation for targeted chemotherapy, gene therapy, and molecular imaging.

Fig. 1 Damage of Blood Vessel Endothelium Layer. (Creative Biolabs Authorized) Fig. 1 Blood vessel endothelium layer damage.

Our Advanced In Vivo Phage Display Platform for Vascular Endothelium

At Creative Biolabs, we have transitioned beyond traditional biopanning. Our service suite incorporates the latest advancements in biotechnology to ensure the highest specificity and translatability of identified clones.

High-Diversity Library Construction

The success of In Vivo Phage Library Screening depends on the initial library's quality and diversity. We offer:

Random Peptide Libraries: Linear and constrained libraries with diversities exceeding 10¹⁰.
Antibody Libraries: Fully human or synthetic scFv/Fab libraries tailored for in vivo stability.
Focus-Specific Libraries: Pre-enriched libraries targeting known endothelial receptor families.

Multi-Species Animal Models

To ensure clinical relevance, we perform screenings in a variety of validated models:

Rodent Models: Standard and transgenic mice/rats for physiological mapping.
Disease-Specific Models: Syngeneic and xenograft tumor models, inflammatory models (LPS-induced), and atherosclerotic models.
Non-Human Primates (NHP): Strategic screening for high-value translational projects.

Integrated NGS and AI Analysis

Traditional "Sanger-only" screening often misses rare but high-affinity clones. Our platform utilizes:

Deep Sequencing (NGS): Tracking the enrichment of millions of clones across multiple rounds of panning.
Bioinformatic Algorithms: Filtering "parasitic" clones (those that replicate faster but don't bind) and identifying consensus motifs.
AI-Driven Prediction: Using machine learning to predict the binding affinity and stability of identified sequences in human vascular environments.

Detailed Service Workflow of In Vivo Phage Library Screening for Vascular Endothelium

Our workflow for Vascular Endothelium Targeting In Vivo Phage Library Screening is meticulously designed to maximize the recovery of organ-specific binders while minimizing non-specific background.

Step 1: Pre-Screening and Library Preparation

Before injection, the library is carefully characterized. In some cases, a "negative selection" or "subtractive panning" step is performed in vitro against non-target cells (e.g., hepatocytes or common fibroblasts) to remove ubiquitous binders.
Step 2: Systemic Administration

The phage library is injected intravenously (usually via the tail vein in rodents). The phages circulate through the entire vascular tree, allowing them to interact with the luminal surface of the endothelium under native physiological flow conditions.
Step 3: Circulation and Homing

We optimize the circulation time (ranging from minutes to hours) based on the target. This allows high-affinity phages to bind their respective endothelial receptors. Our platform also includes "internalization-focused" protocols for ligands that must enter the endothelial cell or cross the Blood-Brain Barrier (BBB).
Step 4: Systemic Perfusion

This is a critical step where Creative Biolabs excels. To remove non-specifically bound or circulating phages, the animal is subjected to extensive systemic perfusion with saline or buffered solutions. This ensures that only the phages tightly bound to the vascular wall are recovered.
Step 5: Tissue Recovery and Phage Elution
Target organs (and control organs) are harvested. We utilize various elution techniques:
- Acid Elution: To recover surface-bound phages.
- Direct Infection: Using tissue homogenates to infect E. coli directly, ensuring even the most internalised phages are captured.
- Microdialysis Recovery: For real-time recovery of phages that have extravasated into the tissue parenchyma.
Step 6: Iterative Amplification and NGS

The recovered phages are amplified and subjected to subsequent rounds of in vivo screening (typically 3-4 rounds). NGS is performed at each round to generate a "fitness landscape" of the library enrichment.
Step 7: Validation
Candidate clones are validated through:
- Ex Vivo Binding Assays: Using primary endothelial cell cultures.
- Immunohistochemistry (IHC): Visualizing phage distribution in tissue sections.
- In Vivo Imaging: Using fluorescent or radiolabeled peptides to confirm real-time homing in live animals.

Applications: Tissue-Specific Targeting Capabilities

Creative Biolabs has successfully mapped various vascular "ZIP codes." Our In Vivo Phage Display expertise extends to the following high-demand areas:

Blood-Brain Barrier (BBB) Targeting

Identifying peptides that can trigger receptor-mediated transcytosis across the BBB is the "holy grail" of CNS drug delivery. We focus on receptors like Transferrin (TfR) and LRP1, but also discover novel, uncharacterized pathways.

Pulmonary Vasculature

The lung's massive surface area makes it an ideal target for treating respiratory distress, pulmonary hypertension, and metastatic cancer. We have identified motifs specific to the lung endothelium that avoid liver and spleen sequestration.

Tumor Neo-Vasculature

Cancerous blood vessels are structurally and molecularly distinct. We screen for ligands targeting:

Angiogenic Markers: VEGFR, Integrins.
Hypoxia-Induced Markers: For targeting the necrotic core of tumors.
Stroma-Vascular Interface: To disrupt the tumor microenvironment.

Table 1. Comparison of Targeting Efficiency across Organ

Target Organ	Common Surface Marker	Enrichment Ratio (Typical)	Lead Motif Example
Brain	LRP1, TfR, GLUT1	10-50x	THR, Angiopep-2
Lung	Aminopeptidase P	20-100x	GFE
Tumor	CD13, αvβ3	50-500x	RGD, NGR
Kidney	Megalin	5-20x	LTS

Why Choose Creative Biolabs?

As the industry's premier provider of In Vivo Phage Library Screening Services, Creative Biolabs provides unparalleled technical depth:

20+ Years of Experience: We have successfully completed thousands of phage display screening projects for global pharmaceutical and biotech leaders.
Proprietary Phage Systems: Including M13, T7, and T4 phage systems, optimized for different environmental stresses.
End-to-End Solutions: From library construction to lead optimization and preclinical validation.
Regulatory Compliance: Our facilities operate under strict quality control standards, ensuring data integrity for your regulatory filings.
Scientific Consultation: Work directly with PhD-level scientists to design a custom screening strategy tailored to your specific molecule and target.

Explore Our Comprehensive Services

To further your research, consider our integrated In Vivo Phage Library Screening Services modules:

Learn more about other Phage Display Library Screening Services:

Creative Biolabs is dedicated to pushing the boundaries of what is possible in vascular targeting. Our expert team is ready to discuss how our Vascular Endothelium Targeting In Vivo Phage Library Screening Service can accelerate your drug discovery program.

Contact Us Today for a Free Quote!

Frequently Asked Questions (FAQs)

Q: What is the main advantage of in vivo phage display over in vitro screening?
A: In vivo screening accounts for the complex physiological environment, including blood flow, enzymatic degradation, and the native 3D conformation of endothelial receptors, which are often lost in cell culture.
Q: How many rounds of panning are typically required for vascular targeting?
A: Usually, 3 to 4 rounds are sufficient to achieve significant enrichment of tissue-specific clones.
Q: Can you target specific parts of an organ, such as the glomerulus in the kidney?
A: Yes, by using specialized histological recovery techniques or laser capture microdissection, we can isolate phages from specific sub-anatomical regions.
Q: What phage types do you use for in vivo screening?
A: We primarily use filamentous M13 phages for peptide display due to their stability, but T7 lytic phages are also available for applications requiring larger inserts or different display properties.
Q: How do you prevent the library from being cleared by the liver or spleen?
A: We use "pre-adsorption" techniques and optimized circulation times. We also offer modified phage scaffolds designed to evade the Reticuloendothelial System (RES).
Q: Is NGS mandatory for your service?
A: While not mandatory, we highly recommend it. NGS provides a much broader view of the library's evolution and helps identify high-affinity binders that might be outcompeted by "faster growers" in traditional Sanger sequencing.
Q: Can the identified peptides be used in humans?
A: The peptides discovered in animal models often require "humanization" or validation in human tissue sections/NHP models, which we also provide. Many motifs (like RGD) are highly conserved across species.
Q: What is the typical library diversity you provide?
A: Our standard libraries have a diversity of 10⁹ to 10¹¹ unique clones.
Q: Do you provide the chemical synthesis of the identified lead peptides?
A: Yes, we provide full peptide synthesis and modification services, including cyclization, D-amino acid substitution, and conjugation to payloads.
Q: How do you ensure the phages are actually binding to the endothelium and not just stuck in the blood?
A: Through rigorous systemic perfusion with high volumes of buffer, which flushes out all non-adherent phages from the vascular lumen.
Q: Can this service be used for identifying biomarkers of vascular inflammation?
A: Absolutely. We can compare phage enrichment between healthy animals and those with induced vascular inflammation to find unique biomarkers of disease.

References

Pemmari, Toini, et al. "Screening of homing and tissue-penetrating peptides by microdialysis and in vivo phage display." Life science alliance 8.5 (2025). https://doi.org/10.26508/lsa.202201490

×

Online Inquiry

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.